These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 16416444

  • 1. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.
    Seneca N, Finnema SJ, Farde L, Gulyás B, Wikström HV, Halldin C, Innis RB.
    Synapse; 2006 Apr; 59(5):260-9. PubMed ID: 16416444
    [Abstract] [Full Text] [Related]

  • 2. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.
    Finnema SJ, Halldin C, Bang-Andersen B, Gulyás B, Bundgaard C, Wikström HV, Farde L.
    Synapse; 2009 May; 63(5):378-89. PubMed ID: 19173265
    [Abstract] [Full Text] [Related]

  • 3. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.
    Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA.
    J Neurochem; 2006 May; 97(4):1089-103. PubMed ID: 16606355
    [Abstract] [Full Text] [Related]

  • 4. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
    Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez D, Kegeles LS, Abi-Dargham A, Laruelle M.
    Synapse; 2004 Jun 01; 52(3):188-208. PubMed ID: 15065219
    [Abstract] [Full Text] [Related]

  • 5. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
    Kodaka F, Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Okumura M, Otsuka T, Nakayama K, Halldin C, Farde L, Suhara T.
    Int J Neuropsychopharmacol; 2011 Feb 01; 14(1):83-9. PubMed ID: 20860881
    [Abstract] [Full Text] [Related]

  • 6. Amphetamine pretreatment induces a change in both D2-Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats.
    Ginovart N, Wilson AA, Houle S, Kapur S.
    Biol Psychiatry; 2004 Jun 15; 55(12):1188-94. PubMed ID: 15184038
    [Abstract] [Full Text] [Related]

  • 7. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.
    Peng T, Zysk J, Dorff P, Elmore CS, Ström P, Malmquist J, Ding M, Tuke D, Werkheiser J, Widzowski D, Mrzljak L, Maier D.
    Synapse; 2010 Aug 15; 64(8):624-33. PubMed ID: 20340171
    [Abstract] [Full Text] [Related]

  • 8. Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.
    Seneca N, Zoghbi SS, Skinbjerg M, Liow JS, Hong J, Sibley DR, Pike VW, Halldin C, Innis RB.
    Synapse; 2008 Oct 15; 62(10):756-63. PubMed ID: 18651641
    [Abstract] [Full Text] [Related]

  • 9. A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey.
    Finnema SJ, Seneca N, Farde L, Shchukin E, Sóvágó J, Gulyás B, Wikström HV, Innis RB, Neumeyer JL, Halldin C.
    Nucl Med Biol; 2005 May 15; 32(4):353-60. PubMed ID: 15878504
    [Abstract] [Full Text] [Related]

  • 10. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system.
    Galineau L, Wilson AA, Garcia A, Houle S, Kapur S, Ginovart N.
    Synapse; 2006 Aug 15; 60(2):172-83. PubMed ID: 16715499
    [Abstract] [Full Text] [Related]

  • 11. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain.
    Otsuka T, Ito H, Halldin C, Takahashi H, Takano H, Arakawa R, Okumura M, Kodaka F, Miyoshi M, Sekine M, Seki C, Nakao R, Suzuki K, Finnema S, Hirayasu Y, Suhara T, Farde L.
    J Nucl Med; 2009 May 15; 50(5):703-10. PubMed ID: 19372485
    [Abstract] [Full Text] [Related]

  • 12. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M.
    Synapse; 2006 Dec 01; 60(7):485-95. PubMed ID: 16952157
    [Abstract] [Full Text] [Related]

  • 13. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.
    Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, Plisson C, Miller SR, Huiban M, Beaver JD, Gunn RN, Laruelle M, Rabiner EA.
    J Cereb Blood Flow Metab; 2012 Jan 01; 32(1):127-36. PubMed ID: 21878947
    [Abstract] [Full Text] [Related]

  • 14. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.
    Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S.
    Hum Brain Mapp; 2008 Apr 01; 29(4):400-10. PubMed ID: 17497628
    [Abstract] [Full Text] [Related]

  • 15. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.
    van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y, Narendran R, Van Heertum R, Laruelle M.
    Neuropsychopharmacology; 2006 May 01; 31(5):967-77. PubMed ID: 16177807
    [Abstract] [Full Text] [Related]

  • 16. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.
    Narendran R, Frankle WG, Mason NS, Rabiner EA, Gunn RN, Searle GE, Vora S, Litschge M, Kendro S, Cooper TB, Mathis CA, Laruelle M.
    Synapse; 2009 Jun 01; 63(6):447-61. PubMed ID: 19217025
    [Abstract] [Full Text] [Related]

  • 17. Effects of amphetamine and evoked dopamine release on [11C]raclopride binding in anesthetized cats.
    Ginovart N, Hassoun W, Le Cavorsin M, Veyre L, Le Bars D, Leviel V.
    Neuropsychopharmacology; 2002 Jul 01; 27(1):72-84. PubMed ID: 12062908
    [Abstract] [Full Text] [Related]

  • 18. Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride.
    Kodaka F, Ito H, Kimura Y, Fujie S, Takano H, Fujiwara H, Sasaki T, Nakayama K, Halldin C, Farde L, Suhara T.
    Eur J Nucl Med Mol Imaging; 2013 Apr 01; 40(4):574-9. PubMed ID: 23238524
    [Abstract] [Full Text] [Related]

  • 19. D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.
    Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB.
    Neuroimage; 2010 May 01; 50(4):1402-7. PubMed ID: 20097293
    [Abstract] [Full Text] [Related]

  • 20. (18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.
    Finnema SJ, Stepanov V, Nakao R, Sromek AW, Zhang T, Neumeyer JL, George SR, Seeman P, Stabin MG, Jonsson C, Farde L, Halldin C.
    J Nucl Med; 2014 Jul 01; 55(7):1164-70. PubMed ID: 24790219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.